MX2023010316A - Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. - Google Patents

Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.

Info

Publication number
MX2023010316A
MX2023010316A MX2023010316A MX2023010316A MX2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A
Authority
MX
Mexico
Prior art keywords
indole derivatives
treatment
agents useful
disorders related
disorders
Prior art date
Application number
MX2023010316A
Other languages
English (en)
Spanish (es)
Inventor
Abdelmalik Slassi
Joseph Araujo
Guy Andrew Higgins
Original Assignee
Mindset Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Pharma Inc filed Critical Mindset Pharma Inc
Publication of MX2023010316A publication Critical patent/MX2023010316A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023010316A 2021-03-02 2022-03-02 Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. MX2023010316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163155634P 2021-03-02 2021-03-02
PCT/CA2022/050296 WO2022183288A1 (en) 2021-03-02 2022-03-02 Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Publications (1)

Publication Number Publication Date
MX2023010316A true MX2023010316A (es) 2023-11-09

Family

ID=83153685

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023010316A MX2023010316A (es) 2021-03-02 2022-03-02 Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
MX2023010317A MX2023010317A (es) 2021-03-02 2022-03-02 Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010317A MX2023010317A (es) 2021-03-02 2022-03-02 Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.

Country Status (11)

Country Link
US (2) US20240166630A1 (https=)
EP (2) EP4301730A4 (https=)
JP (2) JP2024508922A (https=)
KR (2) KR20230154220A (https=)
CN (2) CN117500788A (https=)
AU (2) AU2022229037A1 (https=)
BR (1) BR112023017754A2 (https=)
CA (2) CA3210275A1 (https=)
IL (2) IL305622A (https=)
MX (2) MX2023010316A (https=)
WO (2) WO2022183287A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
KR20250053871A (ko) * 2022-08-31 2025-04-22 사이빈 아이알엘 리미티드 트립타민 화합물, 조성물, 및 사용 방법
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
CN121752545A (zh) * 2023-11-06 2026-03-27 宜昌人福药业有限责任公司 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
PL170330B1 (pl) * 1990-10-15 1996-11-29 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
DE60222396T2 (de) * 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
TWI318621B (en) * 2006-08-03 2009-12-21 Nat Bureau Of Controlled Drugs Dept Of Health A series of deuterium labelled compounds as drug testing standards and their preparations
US20090062367A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched eletriptan
EP2753605B1 (en) * 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US20190358238A1 (en) * 2016-11-16 2019-11-28 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
MX2022009528A (es) * 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20240096817A (ko) * 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법

Also Published As

Publication number Publication date
JP2024508545A (ja) 2024-02-27
KR20230154219A (ko) 2023-11-07
AU2022229037A1 (en) 2023-09-28
JP2024508922A (ja) 2024-02-28
CA3210270A1 (en) 2022-09-09
IL305622A (en) 2023-11-01
EP4301730A1 (en) 2024-01-10
KR20230154220A (ko) 2023-11-07
EP4301747A4 (en) 2025-01-22
CN117242065A (zh) 2023-12-15
EP4301747A1 (en) 2024-01-10
IL305481A (en) 2023-10-01
EP4301730A4 (en) 2025-01-22
BR112023017754A2 (pt) 2023-11-21
WO2022183287A1 (en) 2022-09-09
WO2022183288A1 (en) 2022-09-09
MX2023010317A (es) 2023-11-09
AU2022229695A1 (en) 2023-09-28
CA3210275A1 (en) 2022-09-09
CN117500788A (zh) 2024-02-02
US20240166599A1 (en) 2024-05-23
US20240166630A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
PH12022551981A1 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
MX2023010316A (es) Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
MX2023006652A (es) Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc.
MX2024012865A (es) Derivados de indolina como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos
MX2025001439A (es) Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
TNSN07007A1 (en) 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha -7- nachr ligands for the treatment of cns diseases
PH12012501640A1 (en) Novel compounds as opioid receptor modulators
MX2010002538A (es) 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas.
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
MX2023006063A (es) Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
WO2022115944A8 (en) Carboxylated psilocybin derivatives and methods of using
PH12022500015A1 (en) Ccr6 receptor modulators
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
WO2024054866A3 (en) Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
EA201270421A1 (ru) 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт
MX2025001465A (es) Dimeros de 3-pirrolidina-indol como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos
NO20091831L (no) Indoler
MX2025002501A (es) Derivados de indolina como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos
CR20240353A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa